An Open Label, Multi-Center Phase I/II Study to Evaluate Efficacy and Safety of BGB-290 in Chinese Subjects With Advanced Ovarian Cancer, Fallopian Cancer, and Primary Peritoneal Cancer or Advanced Triple Negative Breast Cancer
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Pamiparib (Primary)
- Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors BeiGene
- 11 Jul 2023 Status changed from active, no longer recruiting to completed.
- 05 Jun 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified 16 Jun 2021 ).
- 29 Nov 2021 protocol amendment initiated a more proactive dose-modification algorithm for instances of hematologic AE